Episode 112

On this week’s Biotech Hangout, hosts Eric Schmidt, Brad Loncar, Brad Skorney, Luba Greenwood and Josh Schimmer kick off the episode summarizing the wild week for biotech stocks. The group also recaps some of the big earning announcements from the week, including a larger discussion on overall learnings from the Q2 earnings season. The hosts discuss Charles River Laboratories as a harbinger of pharma cost cutting and share general perspectives on the IRA impact on pharma. The FDA’s approval of Agios/Servier’s vorasidenib (Voranigo) for glioma was also discussed, with a look back at Servier’s earlier acquisition of Agios’ oncology business. The group also engages in a discussion on muscle disease as a growing area with potential to address large unmet medical needs and highlights some innovative companies in the space. Other topics covered include the Recursion and Exscientia merger, the biotech bubble, the potential impact of the election on the pharma industry and more. *This episode aired on August 9, 2024.